VGSK Technologies Inc., the parent company of ProLung, has created a method for controlled release system for the lungs which can deliver medications into the bloodstream. Our ProLung™ system can create a tremendous opportunity to improve medical therapy in the medically underserved areas around the world. Reductions in drug costs, drug administration and mass drug delivery using a single device, are just some of the advantages of the ProLung system in improving global public health systems.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 504 S Rosa Rd,
- Industry
- Biotechnology
- Website
- vgsktechnologies.com
- Keywords
- prolonged drug delivery technology, once a week delivery to the lungs, intranasal drug delivery-prolonged, subcutaneous drug delivery-prolonged.
- HQ
- Madison, Wisconsin
Vgsk Technologies Inc Questions
Vgsk Technologies Inc's website is vgsktechnologies.com
Vgsk Technologies Inc's LinkedIn profile is https://www.linkedin.com/company/vgsk-technologies-inc
Vgsk Technologies Inc has
4 employees.
View email and phone details for 4
employees at Vgsk Technologies Inc.
Vgsk Technologies Inc's industry is
Biotechnology
Vgsk Technologies Inc's top competitors are
Ambr Genomics,
Rojobio,
Diphex Solutions Limited,
Ayrflo Innovation Labs, Inc.,
Laila Nutraceuticals,
Xylome,
Edara Research Foundation (Erf),
Selight, Llc,
Terra Bioforge,
Axio Biopharma.
Vgsk Technologies Inc's categories are Biotechnology
Vgsk Technologies Inc's founding year is 2014
